Coming soon to Pharmulous Pharmulous is preparing to support eligible patients with oral GLP-1 weight management options once they become available, clinically appropriate and supported by UK guidance
SARS-CoV-2 has been detected in esophageal, gastric, duodenal, rectal, and fecal samples of COVID-19 patients
Benefits may include improved metabolic efficiency, increased energy levels, enhanced muscle recovery, better sleep quality, healthier skin and hair, reduced inflammation, and improved immune response
Jump to: Who should never take weight-loss injections | Conditions that need extra caution | Medications that interact | Pregnancy, breastfeeding and age | If you are scheduled for surgery | When to stop and seek help | Questions to ask your GP | Frequently asked questions | Take home message You shouldnt take weight-loss injections like Wegovy (semaglutide) or Mounjaro (tirzepatide) if you have a personal or family history of medullary thyroid cancer, multiple endocrine neoplasia type 2 (MEN-2), type 1 diabetes, or have had a serious allergic reaction to a GLP-1 medication